Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.06USD
26 May 2017
Change (% chg)

$-0.04 (-1.29%)
Prev Close
$3.10
Open
$3.08
Day's High
$3.17
Day's Low
$3.04
Volume
301,569
Avg. Vol
371,193
52-wk High
$5.11
52-wk Low
$2.86

Latest Key Developments (Source: Significant Developments)

Celldex reports Q1 loss per share $0.28
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Celldex Therapeutics Inc :Celldex reports first quarter 2017 results.Q1 loss per share $0.28.Q1 revenue $1.5 million versus $1.3 million.Q1 revenue view $923,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Q4 revenue $1.9 million versus $5.5 million
Tuesday, 14 Mar 2017 04:01pm EDT 

Celldex Therapeutics Inc : Celldex provides corporate update and reports full year 2016 results . Q4 loss per share $0.30 . Q4 revenue $1.9 million versus $5.5 million . Q4 revenue view $1.1 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex therapeutics - cash, cash equivalents and marketable securities as of dec 31, 2016 were $189.8 million compared to $203.2 million as of sept 30, 2016 . Celldex therapeutics inc says chip catlin, senior vice president and chief financial officer, shared his intention to retire in june this year . Says sam martin, current vice president of finance will be promoted to cfo role concurrent with chip's departure . Celldex therapeutics inc- increase in qtrly revenue was primarily due to clinical trial collaboration with bristol-myers squibb and increase in grant revenue .Celldex therapeutics- cash,cash equivalents,marketable securities at dec 31,enough to meet estimated working capital,fund planned operations through 2018.  Full Article

Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock
Thursday, 26 Jan 2017 04:29pm EST 

Celldex Therapeutics Inc :Files for offering of up to 18.4 million shares of common stock by the selling stockholders.  Full Article

Celldex reports second quarter 2016 results
Monday, 8 Aug 2016 04:01pm EDT 

Celldex Therapeutics Inc : Q2 revenue $1.4 million versus $2.7 million . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex reports second quarter 2016 results . Q2 loss per share $0.32 .Q2 revenue view $850,000 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Celldex reports Q1 loss per share $0.28

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: